© 2020 Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (NASDAQ:MRKR) today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences. Live webcasts of the presentations will be accessible from the investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.
Marker Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Marker’s planned trial investigating safety and efficacy of its novel MultiTAA T cell therapy in patients with post-transplant acute myeloid leukemia (AML).